Contents
23 October 2019
Vol 11, Issue 515
Vol 11, Issue 515
Focus
- Intratumoral CD8+ T cells with stem cell–like properties: Implications for cancer immunotherapy
Intratumoral PD-1+ TCF1+ CD8+ T cells with stem cell–like properties mediate cellular expansion and tumor control in response to immunotherapy.
Research Articles
- A green tea–triggered genetic control system for treating diabetes in mice and monkeys
A green tea–triggered genetic control system was developed for genome/epigenome editing, digital computations, and diabetes therapy in mice and monkeys.
- Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade
Rotavirus vaccines have oncolytic properties and can overcome resistance to anti–PD-(L)1/CTLA-4 via RIG-I activation upon intratumoral administration.
- A rapid triage test for active pulmonary tuberculosis in adult patients with persistent cough
A blood protein signature discriminates active tuberculosis (TB) from other TB-like disease in adults regardless of HIV status.
- Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
A next-generation, broad-spectrum, orally efficacious influenza A and B virus inhibitor is associated with a high genetic resistance barrier.
- Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
First-in-class clinical trial of IL-33 blockade shows inhibition of neutrophil migration into human skin and modulates atopic dermatitis symptoms.
Editors' Choice
- Antagonizing prions
Combination therapy may offer a way to slow the progression of prion diseases.
- Ingestible macromolecule injectors
A next-generation ingestible device uses microneedles for macromolecule administration in the small intestine to avoid subcutaneous injections.
- Biliopancreatic diversion is beyond just weight loss
Biliopancreatic diversion slows glucose absorption and increases insulin sensitivity, which results in better glycemic control than other gastric bypass procedures.
About The Cover
ONLINE COVER Tea Time. The image shows a mouse drinking green tea. Yin et al. used synthetic biology to engineer cells to produce a short variant of human glucagon-like peptide 1 or insulin in response to the green tea metabolite protocatechuic acid (PCA). Diabetic mice and nonhuman primates implanted intraperitoneally with encapsulated engineered cells demonstrated tight control of blood glucose when treated with PCA or after ingesting green tea. This study demonstrates the versatility of synthetic biology for developing engineered cell therapies for diabetes. [CREDIT: YE LABORATORY/EAST CHINA NORMAL UNIVERSITY]
